# This Page Is Inserted by IFW Operations and is not a part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

#### WORLD INTELLECTUAL PROPERTY ORGANIZATION



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

G01N 21/77

A1 (11) International Publication Number: WO 90/14590 (43) International Publication Date: 29 November 1990 (29.11.90)

(21) International Application Number: PCT/GB90/00764

(22) International Filing Date: 17 May 1990 (17.05.90)

(30) Priority data: 8911462.3 18 May 1989 (18.05.89) GB

(71) Applicant (for all designated States except US): ARES-SER-ONO RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP [US/US]; Exchange Place, 37th Floor, Boston, MA 02109 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): ATTRIDGE, John, Worthington [GB/GB]; Croxley East, The Heath, Weybridge, Surrey KT13 0UA (GB). SMITH, Alan, Martin [GB/GB]; 129 Hale Road, Hale, Altrincham, Cheshire WA15 9HQ (GB).

(74) Agent: FRANK B. DEHN & CO.; Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).


(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE\*, DE (European patent)\*, DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DEVICES FOR USE IN CHEMICAL TEST PROCEDURES



#### (57) Abstract

The invention relates to a device for use in methods of assay, for example those involving fluorescent moieties. The device possesses a cavity or cavities into which sample liquid may be drawn by capillary action. Each cavity is formed from two transparent solid plates (35, 36): one (36) is adapted to act as a waveguide and carries a suitable immobilised reagent on its surface within the cavity; the other (35) carries on its external surface and optionally also on part only of its internal surface a layer of light-absorbing material (37). The invention also relates to a method of manufacturing devices according to the invention, and to a method of assaying for a ligand in a sample using a device according to the invention.

#### **DESIGNATIONS OF "DE"**

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT. .

AT	Austria	ES	Spain	МС	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	мw	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	1T	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic	SE	Sweden
CG	Congo		of Korea	SN	Senegal
CH	Switzerland -	KR	Republic of Korea	su	Soviet Union
СМ	Cameroon	LI	Liechtenstein	TD	Chad
DE	Germany, Federal Republic of	LK	Sri Lanka .	TG	Togo
DK	Denmark	LU	Luxembourg	US	United States of America

Se Mar

#### Devices for Use in Chemical Test Procedures

This invention relates to devices for use in chemical, biochemical or clinical test procedures, to processes for their manufacture, and to methods of using the devices.

More particularly, the invention relates to devices suitable for use in specific binding assays, among which an important group is constituted by immunoassays.

Various analytical devices for handling and 10 metering small volumes of test samples have been described in the prior art. In particular, EP-A-171148 describes capillary fill cell devices which can be conveniently manufactured and which are suitable for specific binding assays using very small liquid 15 samples. These devices possess a cavity or cavities each having a dimension small enough to enable sample liquid to be drawn into the cavity by capillary action, wherein a surface of the cavity carries an immobilised reagent appropriate to the test to be carried out 20 in the device, and wherein said surface is a surface of a transparent solid plate adapted to act as a light-transmissive waveguide and forming a wall of the cavity, said plate having an edge which is substantially optically smooth ("the optical edge") and 25 transverse, e.g. at some transverse angle, but most preferably perpendicular, to the plane of the plate. Such devices enable convenient sample collection and optical analysis in situ of the products of reaction of the sample with the said immobilised reagent. 30 The waveguide plate should be transparent to radiation of the wavelength intended to be employed, e.g. infrared, visible and/or ultraviolet light, and one method of using a device as described in EP-A-171148 is

to arrange for a fluorescent material

to become bound to the immobilised reagent to an extent which will vary depending on the assay and the sample material being assayed and then to carry out optical measurement of the resulting bound fluor5 escent material.

EP-A-171148 discloses the possibility that for some forms of assay it may be appropriate for the wall of the capillary cavity opposite to the reagent-bearing waveguide surface to be made of a light-absorbing, opaque or reflective material, i.e. for the device to have the structure depicted in Figure 1, described in more detail later.

The difference in angular distributions of fluorescence arising from fluorophores in the analyte solution and fluorophores bound to the waveguide surface is well known in the art. Under ideal conditions, angular discrimination of fluorescence emerging from the edge of the waveguide would be sufficient to separate the different emission signals. In practice, however, various imperfections in the device can cause fluorescence from the fluorophores in solution to be scattered and to emerge from the optical edge at angles which are normally associated with evanescently coupled fluorescence, i.e. from surface-bound fluorophores.

We have now surprisingly found that this problem can be overcome, with a significantly improved performance over structures described in EP-A-171148 including the structure depicted in Figure 1, if the wall of the capillary cell opposite to the reagent-bearing waveguide surface is formed of a material transparent to radiation of the wavelengths involved in the assay, but a layer of opaque or light-absorbing material is applied to one or more external surfaces of the said transparent material, preferably at least to the external surface parallel to the waveguide.

The term "opaque layer" will be used hereinafter to mean such a layer of opaque or light-absorbing

material.

Thus, according to one aspect of the invention we provide a specifically-reactive sample-collecting and testing device possessing a cavity or cavities 5 each having a dimension small enough to enable sample liquid to be drawn into the cavity by capillary action, one surface of the or each cavity carrying an immobilized reagent appropriate to the test to be carried out in the device, said surface being a surface of a 10 first transparent solid plate adapted to act as a light-transmissive waveguide, said plate having an edge which is substantially optically smooth and transverse to the plane of the plate, said device being characterised in that the wall of the or each cavity opposite 15 to said waveguide comprises a second transparent plate, the second transparent plate carrying on its surface remote from the cavity a layer of light-absorbing or opaque material.

As mentioned above, the first transparent solid 20 plate has an edge-which is transverse to the plane of the plate. The said edge can be at any transverse angle but is most preferably perpendicular.

In an embodiment, the invention also provides a device as described herein for use in the 25 fluoroimmunoassay or luminescent immunoassay of an analyte present in sample liquid, said device comprising a planar capillary cell for the collection and retention of the volume of sample liquid to be tested therein, said capillary cell comprising a pair of flat, parallel 30 plates fixed together with an air space therebetween and sealed along two opposite sides so as to provide fixed opposed inner surfaces defining a capillary cavity with a first aperture at one end thereof to allow ingress of sample liquid in the capillary cavity and a second 35 aperture at the other end thereof to allow egress of air from the capillary cavity as it fills with sample liquid, wherein one of said plates is a lighttransmissive waveguide having an optically smooth edge which is transverse to the plane of the waveguide and

10

15

20

25

30

35

40

perpendicular to the sealed sides thereof, said waveguide having bound to at least a portion of its inner
surface, so as to be contacted in use by the sample
liquid collected within the capillary cavity, an
immobilised reagent capable of binding, either directly
or indirectly, a labelled ligand, wherein said
immobilised reagent and said labelled ligand are
appropriate to the test for analyte to be carried out in
the device, the labelled ligand being releasably
retained within said device so as in use to be contacted
by and released into the sample liquid collected therewithin, and wherein the other plate carries on its
surface remote from the cavity a layer of lightabsorbing or opaque material.

For convenience, the surface of the second transparent plate which carries the layer of light-absorbing or opaque material is referred to herein as the external surface of the said plate, the opposite surface of the plate being referred to herein as the internal surface.

We have found that in some circumstances it may be advantageous if, in addition to the said external surface, part only of the internal surface of the capillary cavity wall, i.e. part only of the internal surface of the second transparent plate, carries light-absorbing or opaque material.

According to a further aspect of the invention we therefore provide a specifically-reactive sample-collecting and testing device possessing a cavity or cavities each having a dimension small enough to enable sample liquid to be drawn into the cavity by capillary action, one surface of the or each cavity carrying an immobilized reagent appropriate to the test to be carried out in the device, said surface being a surface of a first transparent solid plate adapted to act as a light-transmissive waveguide, said plate having an edge which is substantially optically smooth and transverse to the plane of the plate, said device being characterized in that the wall of the or each cavity opposite to said waveguide comprises a second transparent plate, the second transparent

10

15

20

25

30

35

plate carrying on its external surface a layer of light-absorbing or opaque material and also carrying on part only of its internal surface a layer of lightabsorbing or opaque material.

The devices according to the invention may be manufactured by methods broadly similar to those described in EP-A-171148 but with the additional feature of applying a light-absorbing or opaque layer to the appropriate surface(s) of the device.

According to the present invention we also provide a method of manufacturing specifically-reactive sample-collecting and testing devices as described above comprising the steps of

- (a) forming an immobilised specifically-reactive coating on the surface of a sheet material which is to provide part of a multiplicity of the devices,
- (b) forming a light-absorbing or opaque layer on one or more surfaces of an additional structure which together with said coated sheet material provides for each of the multiplicity of devices a cavity of capillary dimension for collecting and retaining by capillarity a volume of sample liquid in contact with the specifically-reactive coating, and
- (c) separating the sheet material into portions each providing one or a plurality of the sample-collecting and testing devices.

In this process, both the specifically-reactive coating and the external opaque layer can be continuous or divided into a pattern, e.g. of discrete portions, for example as a two-dimensional array of patches. Where such patches are formed, they can be made for example either by firstly forming a continuous coating and then removing portions of it to leave the desired pattern, e.g. the array of discrete portions, or as an array of patches (for example, screen-printed). Where part of the internal surface of the cavity wall is to carry an opaque layer, the relevant opaque layer applied during manufacture will of course be applied as a discontinuous layer.

10

15

20

25

30

35

The specifically-reactive coating may be immobilised on the surface of the cavity either directly or indirectly. For example, when the specifically-reactive coating is an antibody, indirect immobilisation may be effected by means of an anti-species antibody which is itself bound to the said surface. Alternatively, immobilisation may be effected by conjugating an antibody with biotin and complexing with avidin pre-immobilised on the said surface. Direct immobilisation may be effected by activating the said surface by treatment with a suitable reagent (e.g. a silanisation reagent such as aminopropyltrimethoxysilane), to which the antibody can be covalently coupled using an appropriate crosslinking reagent (e.g. glutaraldehyde).

As already mentioned with reference to devices of the prior art, one method of using a device according to the invention in an assay for a ligand in a liquid sample is to arrange for a fluorescent material to become bound to the immobilised reagent to an extent which will vary depending on the assay and the sample material being assayed and then to carry out optical measurement of the resulting bound fluorescent material.

A suitable fluorescent material typically comprises an ancillary reagent, being either a ligand analogue labelled with a fluorophore or a specific binding partner to the ligand under assay labelled with a fluorophore. When carrying out an assay, the fluorescent material may be introduced, in known amount, into the liquid sample prior to introducing the sample into the device. Alternatively, the fluorescent material may be pre-immobilised on a surface within the device in a soluble, releasable form, e.g. by means of a soluble humectant coating. In the latter case, introducing the sample liquid into the device dissolves the soluble humectant coating so that the ancillary reagent becomes dispersed in the sample liquid.

10

15

20

25

30

In an embodiment, the invention provides a method as described hereinbefore comprising the steps of:

- (a) immobilising a reagent appropriate to the test to be carried out in the device onto portions of the surface of a transparent flat sheet material which is capable of acting as a light-transmissive waveguide and which is to provide a part of a multiplicity of the devices;
- (b) forming a light-absorbing or opaque layer on one surface of an additional structure;
- (c) either prior to or subsequent to step (b), attaching to said sheet material the said additional structure in parallel, spaced relation thereto so as to provide for each device of the multiplicity of devices a capillary cavity sealed along two opposite sides thereof and containing the immobilised reagent on at least a portion of the inner surface thereof, said capillary cavity being adapted for collecting and retaining by capillarity a volume of sample liquid in contact with said immobilised reagent; and
- (d) separating the assembled sheets into portions, each portion providing one or a plurality of the sample collecting and testing devices, such that the transparent sheet material of each device has at least one optically smooth edge transverse to the plane of the sheet and perpendicular to the sealed sides thereof.

30

The term "ligand analogue" as used herein refers to a species capable of complexing with the same binding site of the same specific binding partner as the ligand under assay, and includes <u>inter alia</u> within its scope a known quantity of the ligand under assay.

Suitable materials for the opaque layer defined hereinbefore are, for example, black paint, optionally curable by heat or infrared radiation, silicone paint, dyes, or any other (preferably inert) material with suitable optical and other physical properties.

Such materials should attenuate or absorb light at least at the wavelengths involved in the assay.

The thickness of the opaque layer of material will typically be a minimum of 3 microns.

The invention is particularly described herein with reference to fluorescence but it will be understood that analogous considerations...apply to phosphorescence and luminescence.

For a better understanding of the present invention, reference is made to the accompanying drawings wherein:-

Figure 1 shows a diagrammatic section through a variant of a capillary fill device suggested in EP-A-171148.

Figures 2 to 6 show diagrammatic sections through capillary fill devices according to different embodiments of the present invention.

Figure 7 shows a plan view of the capillary fill device of the invention shown as a section in Figure 5.

Figure 8 shows in schematic form attenuation of solution fluorescence in the device of figure 2.

Figure 9 shows in schematic form attenuation

of solution fluorescence in the device of figure 3.

Figure 10 shows schematically a simple apparatus suitable for carrying out an assay in accordance

10 with the invention.

Referring to figure 1, the device depicted comprises an upper transparent (e.g. plastics, silica or glass) plate 1 and a lower transparent plate 2, both plates being around 1 mm thick fixed together 15 in substantially parallel relation, less than 1 mm apart, by means of bonding tracks (not shown) of suitable adhesive. The cell cavity 3 so formed is open to the outside at both ends, so that when liquid sample is drawn into one opening of the cavity by 20 means of capillarity, air may escape through the other opening. The lower plate 2 of the device is larger than plate 1, the former having a section 4 which extends away from the aperture. In use, section 4 of plate 2 acts as a retentive platfrom onto which 25 a drop of sample liquid can be applied, so that this liquid can be made to fill the cell cavity 3 by capillary flow.

Immobilised on the inner surface of the capillary cell is a layer 5 of material relevant to the test

30 for which the device is to be employed. In figure 1, the layer 5 is a patch of material carried on plate

2. In the case of an immunoassay, the layer 5 may be for example a relevant immobilised antibody.

More than one such layer may be present, either in

35 superimposed or adjacent relationship.

Carried on plate 1 on the inner surface of the cell is a layer 6 of light-absorbing or opaque

material, the material being appropriate to the nature of the test for which the device is intended to be used and the wavelengths of light intended to be employed.

Figure 2 shows a diagrammatic section through a capillary cell device according to an embodiment of the present invention. The device comprises an upper transparent plate 7 and a lower transparent plate 8 related as in figure 1. A reactive layer 9 10 is present on the surface of the plate 8. The plate 7 carries on the external surface thereof an opaque layer 10

Figure 3 shows a diagrammatic section through a capillary cell device according to a further embodiment 15 of the present invention. The plates 11 and 12 are present in the same relation as in figures 1 and 2; the reactive layer 13 may be disposed as before. In this embodiment, plate 11 carries an opaque layer 14 on its outside surface and a layer 15 of similar 20 or identical material on part only of its opposite surface (i.e. on the inner surface of the cell cavity).

Figure 4 shows a diagrammatic section through a capillary cell device according to a further embodiment of the present invention. An opaque layer 16 is 25 disposed on the outside surface of the upper plate 17, as for the embodiment shown in Figure 2. In the embodiment shown in Figure 4, however, the upper and lower plates 17 and 18 are offset so that each plate has a section which may act as a retentive 30 platform, analogous to the section 4 shown in Figure 1.

Figure 5 shows a diagrammatic section through a capillary cell device according to another embodiment of the present invention. Again, an opaque layer 21 is disposed on the outside surface of the upper plate 35 22. In this case, however, the ends of the upper and lower plates are aligned such that there is no retentive platform.

Figure 6 shows a diagrammatic section through a capillary cell device according to another embodiment of the invention. This embodiment is a variant of that shown in Figure 2, having as an additional feature a layer 23 of soluble humectant material containing a suitable fluorescent material on the internal surface of the upper transparent plate 24.

Figure 7 shows a plan view of the device shown in Figure 5. The opaque layer 25 is shown as the central region. The upper plate and lower plate are held in the desired relative positions by means of bonding tracks 26 and 27 of a suitable adhesive incorporating glass ballotini of suitable diameter to produce a gap of capillary dimension (e.g. 100 microns).

Figure 8 shows schematically the paths followed by a typical ray of fluorescent light arising from a fluorophore in solution and by a typical ray of fluorescent light arising from a surface-bound fluorophore 20 in a device of the present invention according to figure 2. Refraction at the sample/glass interface causes certain rays of light emitted from solution fluorophores to propagate in the upper plate 35 at angles to the normal at the interface which are smaller 25 than the critical angle for the interface (for a sample solution/glass interface, these angles would typically lie in the range 0° to 60° to the normal). These rays undergo attenuation on interaction with the opaque layer 37. Fluorescent molecules bound 30 to the reagent immobilised on the surface of the lower glass plate 36 (i.e. within the evanescent field) emit light into the lower plate 36 over the whole range of angles (i.e. including angles to the normal which are greater than the critical angle at 35 the interface of the sample and the lower plate) as a result of evanescent wave coupling. Some of these rays are "guided" through the lower plate, and will emerge

from the end 38 without having interacted with the opaque layer 37. The discrimination between fluorescence arising from surface-bound fluorophores and from solution fluorophores is thereby markedly enhanced.

Figure 9 shows schematically the paths of fluorescent light rays arising from solution fluorophores in the device of figure 3. In this situation, some of the rays of light resulting from solution fluorescence undergo not only attentuation at opaque layer 39, 10 but further attenuation at opaque layer 40, and so on as a result of 'partial reflection'. Rays interacting with both layers 39 and 40 cannot emerge from end 41 and so use of layer 40 may lead to yet further discrimination between fluorescence arising from surface-15 bound fluorophores and that from solution fluorophores, and so increase sensitivity.

Figure 10 shows in schematic form a simple fluorimetry apparatus suitable for use in connection with the present invention. Specific examples of 20 the various components are given hereinafter in Comparative Example A.

Light from a suitable source 51 is roughly collimated by a lens 52 before passing through a filter stack 53, which defines the range of wavelengths 25 used to excite fluorophores taking part in the assay. A further lens 54 focuses this light onto the desired region of the test device 56 through an aperture 55.

Light emerging from a suitable edge of the test device 56 (the "emitted light") passes through 30 an aperture 57 and then through one or more lenses 58. A further aperture 59 is used to define the angular range over which the emitted light is monitored. A further filter 60 is used to remove light of certain wavelengths (e.g. light of excitation wavelengths) 35 and another lens 61 focuses the remaining emitted light onto a photodetector 62.

The invention also provides a method of assaying

for a ligand in a sample using a device according to the invention, said method comprising:

- (a) incubating the sample in contact with the surface of a waveguide, said waveguide being part of said device wherein the immobilised reagent adsorbed thereon or bound thereto, either directly or indirectly, is a specific binding partner for the ligand it is desired to detect, such that during incubation an ancillary reagent (being either a ligand analogue labelled with a fluorophore or a further specific binding partner labelled with a fluorophore) becomes bound, either directly or indirectly, to the surface of said waveguide;
- 15 (b) irradiating said device with light from a suitable light source such that ancillary reagent present in the sample liquid and ancillary reagent bound to the waveguide become excited; and
- 20 (c) monitoring the radiation emerging from said waveguide in order to determine whether and, if desired, the extent to which ancillary reagent has become bound to said waveguide due to complex formation.
- When, in the method of assay according to the invention, the device used is an embodiment the second transparent plate of which carries a layer of light-absorbing or opaque material on both its external surface and part only of its internal surface, the part of the internal surface of the said second plate not carrying light-absorbing or opaque material will be the part which lies opposite the area of the first plate which is irradiated with light from the light source.

WO 90/14590 PCT/GB90/00764

The method of the invention is particularly applicable to assays of antigens or antibodies, i.e. to immunoassays, and in a preferred embodiment of the invention the ligand is an antigen and the specific binding partner comprises an antibody to the said antigen. However, the invention is not to be taken as limited to assays of antibodies or antigens. Examples of ligands which may be assayed by the method of the invention are given in Table 1 below, together with an indication of a suitable specific binding partner in each instance.

Table 1

Ligand	Specific Binding Partner
antigen	specific antibody
antibody	antigen
hormone	hormone receptor
hormone receptor	hormone
polynucleotide strand	complementary polynucleotide strand
avidin	biotin
biotin	avidin
protein A	immunoglobulin
immunoglobulin	protein A
enzyme	<pre>enzyme cofactor (substrate) or inhibitor</pre>
enzyme cofactor (substrate) or inhibitor	enzyme
lectins	specific carbohydrate
specific carbohydrate of lectins	lectins

The method of the invention has very broad applicability but in particular may be used to assay: hormones, including peptide hormones (e.g. thyroid stimulating hormone (TSH), luteinising hormone (LH), but human chorionic gonadotrophin (hCG), follicle stimulating hormone (FSH), insulin and prolactin) or non-peptide hormones (e.g. steroid hormones such as cortisol, estradiol, progesterone and testosterone, or thyroid hormones such as thyroxine (T4) and triiodothyronine), proteins (e.g. carcinoembryonic antigen (CEA) and alphafetoprotein (AFP)), drugs (e.g. digoxin), sugars, toxins, vitamins, proteins, viruses such as influenza,

15 It will be understood that the term "antibody" used herein includes within its scope:

para-influenza, adeno-, hepatitis, respiratory and

- (a) any of the various classes or sub-classes of immunoglobulin, e.g. IgG, IgA, IgM, or IgE derived from any of the animals conventionally used, e.g. sheep, rabbits, goats or mice,
- (b) monoclonal antibodies,

AIDS viruses, or microorganisms.

(c) intact molecules or "fragments" of antibodies,
monoclonal or polyclonal, the fragments being
those which contain the binding region of the
antibody, i.e. fragments devoid of the Fc portion
(e.g. Fab, Fab', F(ab')<sub>2</sub>) or the so-called
"half-molecule" fragments obtained by reductive
cleavage of the disulphide bonds connecting
the heavy chain components in the intact antibody.

The method of preparation of fragments of antibodies is well known in the art and will not be described herein.

The term "antigen" as used herein will be understood to include both permanently antigenic species 35 (for example, proteins, bacteria, bacterial fragments, cells, cell fragments and viruses) and haptens which may be rendered antigenic under suitable conditions. Examples of fluorophores which may be used in the method of assay according to the invention include fluorescein isothiocyanate (FITC), rhodamine isothiocyanate, lucifer yellow, 2,4-dinitrofluorobenzene, phenylisothiocyanate and dansyl chloride, XRITC, TRITC and phycobiliproteins (e.g. allophycocyanin and phycoerythrin).

The present invention further provides apparatus suitable for use in the method of assay according

10 to the invention as hereinbefore described which comprises a source of radiation capable of being arranged such that, in use, it enters a device according to the invention as hereinbefore described at such an angle that both the bound and free fluorophores

15 are excited and means for monitoring the emerging radiation. In a further embodiment, the device can be illuminated via a mask, thereby defining the effective volume of the device in which the binding reaction occurs. The effective volume is the product of the

20 distance between base and top plates of the device and the area of the illumination zone.

#### Comparative Example A

An Optical Immunoassay for Human Chorionic Gonadotrophin (hCG) carried out using a cell with no opaque layer

#### Preparation of Starting Materials

(i) Fabrication of antibody-coated waveguides

A sheet of Permabloc glass (Pilkington Glass
Ltd., St Helens, UK) having a thickness of 1 mm was
cleaned with detergent (e.g. Tween 20) in ultra-pure
water with ultrasonic agitation. The surface of
the glass was activated by incubating it in a 2%

solution of aminopropyltriethoxysilane in water at

a pH of 3 to 4 for two hours at 25°C. After rinsing in water, the glass sheet was dried at 115°C for more than four hours. The glass was then incubated for 60 minutes in a 2.5 % solution of glutaraldehyde
5 in a 0.05 M phosphate buffer (pH 7), and then washed thoroughly with distilled water. The glass was incubated for two to four hours in a 1 percent solution of a monoclonal antibody against hCG in phosphate buffer. The glass sheet was then washed with buffer solution.
10 Unwanted adsorbed protein was removed by soaking with a 6M urea solution in known manner.

#### (ii) Fabrication of Test Devices

Test devices such as have been described in EP-A-171148 were fabricated by screen printing onto 15 the wavequide baseplate resulting from step (i) bonding tracks of an ultraviolet curing glue (UVS 91, Norland Inc., USA) containing glass microspheres of diameter 100 microns (Jencons Ltd., UK) in a pattern defining the long edges of the capillary cell devices. A 20 clear sheet of Permabloc glass was then placed over the waveguide baseplate, and a vacuum applied to the laminate. As result of the vacuum, the upper sheet of glass was caused to press down onto the glue, the glass microspheres defining a gap of 100 25 microns between the glass sheets. The laminate was then exposed to an ultraviolet light source in order to cure the glue. Finally, the laminate sheet was broken up into individual test devices using a standard glass scribing and breaking technique.

# 30 (iii) Preparation of anti-hCG antibody conjugated to fluorescein isothiocyanate (FITC)

200 mg of FITC (Sigma Chemical Company Ltd.,
UK) and 5 mg of a second monoclonal antibody to hCG
specific for a different antigenic determinant were
35 mixed together in 1.4 ml of 0.2 M sodium bicarbonate

buffer solution (pH 9.0). The mixture was left for 18 hours at room temperature, during which conjugation of FITC to the monoclonal antibody occurred. The mixture was then purified by gel filtration on Sephadex 5 G-50 superfine.

#### (iv) Preparation of hCG standard solutions

A freeze-dried preparation of hCG calibrated against the first international reference preparation (75/537) was obtained from Biodata SpA, Milan, Italy.

10 This sample was diluted in horse serum (Serono Diagnostics Ltd., Woking, UK) to give the range of hCG standards required.

## (v) Apparatus used in the measurement of the hCG assay

- Figure 10 shows a simple fluorimetry apparatus which was used to make suitable assay measurements. Light from a xenon flash lamp 51 (Heinmann) is roughly collimated by a lens 52 before passing through a filter stack 53 which defines the wavelength range used to excite the FITC-labelled antibodies. The filter stack comprises three filters: A BG7 Schott glass filter (Ealing Electro Optics UK Ltd., Watford, UK) a 450-480 nm FITC bandpass interference filter (Optometrics Ltd., UK) and a 475 nm shortpass interference filter ference filter (Comar Instruments Ltd., Cambridge, UK). A second lens 54 focused the excitation light onto the active surface of the test cell 56 through an aperture 55 which defines the illuminated area
- Light emitted from the optical edge of the test cell passes through an aperture 57 which prevents light emitted directly out of the solution from entering the detection optics. A lens system 58 collects the emitted light and an aperture 59 defines the angular range over which the emission is measured.

and hence the active volume of the test cell.

This was chosen to coincide with angles associated with evanescently coupled fluorescence emission.

A Schott OG515 515 nm colloidal glass longpass filter 60 (Ealing Electro Optics UK Ltd., Watford, UK) filters out any scattered pump light and a second lens 61 focuses the emission onto a photomultiplier detector 62 (Hamamatsu R931A, Hakuto UK Ltd.).

#### Assay Procedure for hCG

The ahCG-FITC conjugate was added to each of the hCG standards to give about 0.5 ml of test solution. The conjugate concentration was 1 µg/ml. Eight test cells were chosen and each was filled with a different test solution. The cells were read after a twenty

15 minute incubation in a humid environment at 20°C. The standard curve thus generated is shown in Figure 11 for a cell device with no opaque layer. The background signal from 'solution fluorophore' is high, giving rise to a poor signal-to-background ratio which results in poor assay sensitivity.

#### Comparative Example B

An Optical Immunoassay for hCG performed in cells
with an opaque layer on the internal surface of the device (see Fig. 1)

#### Preparation of Starting Materials

(i) <u>Fabrication of Antibody Coated Waveguides</u>

30 See Comparative Example A.

#### (ii) Fabrication of Test Cells

Permabloc glass was washed using detergent and ultrasonic agitation. After drying the glass, the desired pattern of opaque layers was screen

printed, using black ink, on the surface. After thermally curing the printed opaque material, this sheet of glass was substituted for the untreated Permabloc glass of Comparative Example A taking care to ensure that the opaque material was on the inside of the devices prior to lamination. The remainder of the test cell fabrication process was the same as described in Comparative Example A. Test cells as illustrated in Figure 1 resulted.

- 10 (iii) <u>Preparation of anti-hCG conjugated to FITC</u>
  As in Comparative Example A.
  - (iv) <u>Preparation of hCG Standard Solutions</u>
    As in Comparative Example A.
- (v) Apparatus used in the measurement of the assay
   As in Comparative Example A.

#### Assay Procedure for hCG

The assay procedure used was identical to that described in Comparative Example A, except that four cells were tested with each of the hCG test solutions.

In Figure 12 the results of this example are compared to those from Comparative Example A. The presence of an opaque layer has reduced the background signal considerably. As a result there is an improvement in signal-to-background ratio from 1.2:1 to 3:1 for 1000 mIU/mL hCG, therby improving assay sensitivity.

#### Example 1

30 An Optical Immunoassay for hCG performed in cells with an opaque layer on the external of the device (see Fig. 2)

#### Preparation of Starting Materials

- (i) <u>Fabrication of Antibody Coated Waveguides</u>
  As in Comparative Example A.
- (ii) <u>Fabrication of Test Cells</u>

  The method of fabrication of the test cells

5 was the same as in Comparative Example B except that care was taken to ensure that the opaque layers were kept on the outside of the cell during the fabrication process. Test cells illustrated schematically in Figure 2 resulted.

- 10 (iii) Preparation of anti-hCG conjugated FITC
  As in Comparative Example A.
  - (iv) <u>Preparation of hCG Standard Solutions</u>
    As in Comparative Example A.
- (v) Apparatus used in the measurement of the assay15 As in Comparative Example A.

#### Assay Procedure for hCG

As for Comparative Example B. Figure 13 shows the results from this example and those of Comparative 20 Example B. The standard curves are comparable for each of the cell types. With the opaque layer on the outside of the cell, however, assay precision is increased. (Precision across the curve for the external opaque layer is 4.6% compared with 8.0%

- 25 for the internal opaque layer; therefore increased assay performance is achieved by this increase in precision). This arises because the cell gap uniformity, and hence sample volume interrogated, is now defined by the glass surface and not the print quality of
- 30 the opaque layer.

#### Example 2

#### An Optical Immunoassay for hCG performed in cells Possessing opaque layers disposed as in Fig. 3

5 (i) <u>Fabrication of Antibody Coated Waveguides</u>
As for Comparative Example A.

#### (ii) Fabrication of Test Cells

A full pattern of opaque material was printed and cured on a sheet of Permabloc glass according

10 to the method described in Comparative Example B. Following this the glass was turned over and a second full pattern was printed on this reverse side in register with the first print. Following curing, half of the second print was removed using a suitable solvent to leave a pattern with half the length but the same width. After cleaning in detergent with ultrasonic agitation a glass laminate was prepared as described in Comparative Example B. Care was taken to ensure that the less extensive print was inside the cell. After curing the glue, the test cells were separated in the usual manner. Test cells illustrated schematically in Figure 3 resulted.

- (iii) Preparation of anti-hCG conjugated FITC
  As in Comparative Example A.
- 25 (iv) <u>Preparation of hCG Standard Solutions</u>
  As in Comparative Example A.
  - (v) Apparatus used in the measurement of the assay
    As in Comparative Example A.

#### 30 Assay Procedure for hCG

As for Comparative Example B. Figure 14 shows the results from this example and those of Comparative

Example B. The standard curves are again comparable though there is a slight reduction in background signal (from 1.0 to 0.9) over the cells from Comparative Example B. For some cell geometries, e.g. shorter test cells, the greater effectiveness of this arrangment in removing unwanted 'solution signal' could have a more significant effect on assay performance.

#### Example 5

10

An Optical Immunoassay for hCG performed on a cell with differing lengths of external opaque layers

#### Preparation of Starting Materials

- 15 (i) <u>Fabrication of Antibody Coated Waveguides</u>
  As for Comparative Example A.
  - (ii) <u>Fabrication of Test Cells</u>
    As for Example 1
- (iii) Preparation of anti-hCG conjugated FITC20 As in Comparative Example A.
  - (iv) Preparation of Test Solution

    A test solution of 1 µg/ml of conjugate in horse serum was used for this example.
- (v) Apparatus used in the measurement of the assay
   25 As in Comparative Example A.

#### Assay Procedure for hCG

A cell was filled with the zero hCG standard test solution and a reading was taken. The opaque 30 layer was reduced in length by 1 mm from the optical edge end using a scalpel and a second reading was

taken. This procedure was repeated until no opaque material remained.

In Figure 15 the typical response as a function of opaque layer length is shown. Opaque layer length is defined as the distance from the rear of the illumination zone to the front edge of the opaque layer in the direction of the optical edge. The results show that for the cell geometry used a length of around 15 mm measured from the edge of the illumination area distal to the optical edge is sufficient to remove effectively the solution signal, decreasing the background signal to a minimum, thereby enhancing the sensitivity of the device (i.e. improving the signal-to-background ratio).

10

15

30

#### Claims:

- A specifically-reactive sample-collecting and ı. testing device possessing a cavity or cavities each having a dimension small enough to enable sample liquid to be drawn into the cavity by capillary action, one surface of the or each cavity carrying an immobilised reagent appropriate to the test to be carried out in the device, said surface being a surface of a first transparent solid plate adapted to act as a lighttransmissive waveguide, said plate having an edge which is substantially optically smooth and transverse to the plane of the plate, said device being characterised in that the wall of the or each cavity opposite to said waveguide comprises a second transparent plate, the second transparent plate carrying on its surface remote from the cavity a layer of light-absorbing or opaque material.
- A device as claimed in claim 1 wherein the second transparent plate carries on its surface remote from the cavity a layer of light-absorbing or opaque material and also carries on part only of its surface adjacent to the cavity a layer of light-absorbing or opaque material.
- A device as claimed in claim 1 or claim 2 wherein a surface of the or each cavity carries, in a soluble, releasable form, a fluorescent ancillary reagent
   appropriate to the test to be carried out in the device.
  - 4. A device as claimed in claim 3 for use in the assay of a ligand wherein the ancillary reagent is either a fluorophore-labelled specific binding partner to the ligand to be tested or a fluorophore-labelled ligand analogue.

- A device as claimed in claim 1 for use in the 'fluoroimmunoassay or luminescent immunoassay of an analyte present in sample liquid, said device comprising a planar capillary cell for the collection and retention 5 of the volume of sample liquid to be tested therein, said capillary cell comprising a pair of flat, parallel plates fixed together with an air space therebetween and sealed along two opposite sides so as to provide fixed opposed inner surfaces defining a capillary cavity with a first aperture at one end thereof to allow ingress of 10 sample liquid in the capillary cavity and a second aperture at the other end thereof to allow egress of air from the capillary cavity as it fills with sample liquid, wherein one of said plates is a lighttransmissive waveguide having an optically smooth edge 15 which is transverse to the plane of the waveguide and perpendicular to the sealed sides thereof, said waveguide having bound to at least a portion of its inner surface, so as to be contacted in use by the sample liquid collected within the capillary cavity, an 20 immobilised reagent capable of binding, either directly or indirectly, a labelled ligand, wherein said immobilised reagent and said labelled ligand are appropriate to the test for analyte to be carried out in the device, the labelled ligand being releasably 25 retained within said device so as in use to be contacted by and released into the sample liquid collected therewithin, and wherein the other plate carries on its surface remote from the cavity a layer of light-30 absorbing or opaque material.
  - 6. Use of a device as claimed in any one of claims 1 to 5 in an assay for a ligand.
  - 7. A method of manufacturing specifically-reactive sample-collecting and testing devices as claimed in any

PCT/GB90/00764

5

10

15

20

25

35

one of claims 1 to 5 comprising the steps of:

- (a) forming an immobilised specifically-reactive coating on the surface of a sheet material which is to provide part of a multiplicity of the devices;
- (b) forming a light-absorbing or opaque layer on one surface of an additional structure;
- (c) either prior to or subsequent to step (b), attaching the said sheet material to the additional structure so as to provide for each of the multiplicity of devices a cavity of capillary dimension for collecting and retaining by capillarity a volume of sample liquid in contact with the specificallyreactive coating, and so that the lightabsorbing or opaque layer is remote from the cavity; and
- (d) separating the sheet material into portions each providing one or a plurality of the sample-collecting and testing devices.
- 8. A method as claimed in claim 7 comprising the steps of:
  - (a) immobilising a reagent appropriate to the test to be carried out in the device onto portions of the surface of a transparent flat sheet material which is capable of acting as a light-transmissive waveguide and which is to provide a part of a multiplicity of the devices;
- 30 (b) forming a light-absorbing or opaque layer on one surface of an additional structure;
  - (c) either prior to or subsequent to step (b), attaching to said sheet material the said additional structure in parallel, spaced relation thereto so as to provide for each

WO 90/14590 PCT/GB90/00764

5

10

15

(d)

- 28 -

device of the multiplicity of devices a capillary cavity sealed along two opposite sides thereof and containing the immobilised reagent on at least a portion of the inner surface thereof, said capillary cavity being adapted for collecting and retaining by capillarity a volume of sample liquid in contact with said immobilised reagent; and separating the assembled sheets into portions, each portion providing one or a plurality of the sample collecting and testing devices, such that the transparent sheet material of each device has at least one optically smooth edge transverse to the plane of the sheet and perpendicular to the

A method as claimed in claim 7 or claim 8 wherein step (b) is effected prior to step (c) and comprises forming a light-absorbing or opaque layer on opposite
 surfaces of the additional structure.

sealed sides thereof.


- 10. A method of assaying for a ligand in a sample using a device as claimed in any one of claims 1 to 5, said method comprising:
- (a) incubating the sample in contact with the


  surface of a waveguide, said waveguide being
  part of said device wherein the immobilised
  reagent adsorbed thereon or bound thereto,
  either directly or indirectly, is a specific
  binding partner for the ligand it is desired
  to detect, such that during incubation an
  ancillary reagent (being either a ligand
  analogue labelled with a fluorophore, or a
  further specific binding partner labelled


with a fluorophore) becomes bound, either directly or indirectly, to the surface of said waveguide;

- (b) irradiating said device with light from a suitable light source such that ancillary reagent present in the sample liquid and ancillary reagent bound to the waveguide become excited; and
- (c) monitoring the radiation emerging from said
  waveguide in order to determine whether and,
  if desired, the extent to which ancillary
  reagent has become bound to said waveguide
  due to complex formation.
- 11. A method as claimed in claim 10 wherein the 15 ligand is an antigen and the or each specific binding partner comprises an antibody to the said antigen.
- 12. Apparatus for use in a method of assay as claimed in claim 10 or claim 11 which comprises a source of radiation capable of being arranged such that, in use, it enters a device as claimed in any one of claims 1 to 5 at such an angle that both ancillary reagent present in the sample liquid and ancillary reagent bound to the waveguide become excited, and means for monitoring the radiation emerging from the device.
- 25 13. Apparatus as claimed in claim 12 further comprising an illumination mask which, in use, defines the effective volume of the device in which the assay is effected.


1/6










2/6









3/6







SUBSTITUTE SHEET








FIG. 11








### SUBSTITUTE SHEET





#### INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/00764

<del> </del>		101/	20/00/04
	SIFICATION OF SUBJECT MATTER (if several classificati		
_ `	to International Patent Classification (IPC) or to both National	Classification and IPC	
IPC <sup>5</sup> :	G 01 N 21/77		
II. FIELD	S SEARCHED		
	Minimum Documentation	on Searched 7	
Classificati	on System   Clas	alfication Symbols	
IPC <sup>5</sup>	G 01 N, B 01 L		
	Documentation Searched other than to the Extent that such Documents are		
	to the Extent mat soon occuments are	HICIOCCO III IIIC VICEO COLI	
	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of Document, 11 with Indication, where appropri	ate, of the relevant passages 12	Relevant to Claim No. 13
-areaor y	I amount a popularity with management and a popularity		
A	EP, A, 0103426 (BLOCK, MY	RON J.)	1
	21 March 1984		
	see abstract; figure	1; page 26,	
	lines 24-27		i I
A	EP, A, 0171148 (UNILEVER	PLC)	1,7,10,12
	12 February 1986		, , _ , , _ ,
	see figure 1; page 4,	lines 15-22;	
	page 12, line 32 - pa page 15, line 29 - pa	ge 15, line 10;	1
	page 15, line 29 - pa	ge 16, line 2	
	(cited in the application	1)	
Α	EP, A, 0170376 (UNILEVER	NV)	10,12
	5 February 1986	•	
	see figures 1,4a,b; p		
	21 - page 13, line 7;	page 19, line	İ
	16 - page 20, line 6		1
			1
			1
	al categories of cited documents: 19 cument defining the general state of the art which is not	'T" later document published after to or priority date and not in confli	ct with the application but
cor	sidered to be of particular relevance	cited to understand the principle invention	
filir	ng date	"X" document of particular relevant cannot be considered novel or	ce; the claimed invention cannot be considered to
"L" doc	nument which may throw doubts on priority claim(s) or ich is cited to establish the publication date of another	involve an inventive step  'Y" document of particular relevant	_
Cill	ition or other special reason (as specified) cument referring to an oral disclosure, use, exhibition or	cannot be considered to involve document is combined with one	an inventive step when the or more other such docu-
oth	er means	ments, such combination being ( in the art.	phylous to a person skilled
"P" doc	cument published prior to the international filing date but or than the priority date claimed	'A" document member of the same (	patent family
IV. CERT	TIFICATION		•
		ate of Mailing of this International Se	PPP**PQQ
15th	August 1990	26/	שבר. ושש
1-1-1-1		Ignature of Authorized Officer	1
Internation		-gristian or Audiorized Difficult	
	EUROPEAN PATENT OFFICE		SS T. TAZELAAR

Form PCT/ISA/210 (second sheet) (January 1985)

### ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9000764 SA 37115

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/09/90

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0103426	21-03-84	US-A- 4447546 JP-A- 59081560	
EP-A- 0171148	12-02-86	AU-A- 2967289 AU-B- 583040 AU-A- 4491085 AU-B- 588245 AU-A- 4491185 AU-B- 581669 AU-A- 4491385 CA-A- 1231136 CA-A- 1246891 CA-A- 1261256 EP-A,B 0170375 EP-A,B 0170376 WO-A- 8600138 WO-A- 8600138 JP-T- 61502418 JP-T- 61502420 US-A- 4810658	20-04-89 10-01-86 14-09-89 10-01-86 02-03-89 10-01-86 05-01-88 20-12-88 26-09-89 05-02-86 05-02-86 03-01-86 03-01-86 23-10-86 23-10-86
EP-A- 0170376	05-02-86	AU-A- 2967289 AU-B- 583040 AU-A- 4491085 AU-B- 588245 AU-A- 4491185 AU-B- 581669 AU-A- 4491385 CA-A- 1231136 CA-A- 1246891 CA-A- 1261256 EP-A- 0171148 EP-A, B 0170375 WO-A- 8600135 WO-A- 8600135 JP-T- 61502418	20-04-89 10-01-86 14-09-89 10-01-86 002-03-89 10-01-86 005-01-88 20-12-88 26-09-89 12-02-86 005-02-86 003-01-86 003-01-86

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

#### ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9000764

SA 37115

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/09/90

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Pate me	nt family mber(s)	Publication date	
EP-A- 0170376		JP-T- JP-T- US-A-	61502419 61502420 4810658	23-10-86 23-10-86 07-03-89	
nore details about this annex : see					